Form 4: AbbVie Executive Perry C. Siatis Reports Stock and Option Transactions
SEC Form 4
EVP, GC AND SECRETARY Perry C. Siatis reports acquisition of AbbVie shares through performance share awards and stock options, along with the release of performance-vesting restrictions.
Summary
- Perry C. Siatis, an Executive Vice President, GC AND SECRETARY at AbbVie, filed a Form 4 detailing changes in beneficial ownership.
- On February 13, 2025, Siatis acquired shares of AbbVie common stock through performance share awards and performance-vesting restricted stock unit awards granted in 2022, 2023 and 2024.
- The performance-vesting restrictions on these shares were released upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors.
- Siatis also acquired 21,875 options to buy AbbVie common stock at an exercise price of $192.86.
- The options were granted on February 13, 2025, and become exercisable in annual increments starting February 13, 2026.
- The shares related to the performance share awards will be issued to Siatis on February 28, 2025.
- Following these transactions, Siatis directly owns 28,159 shares of AbbVie common stock and 21,875 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the vesting of performance-based awards suggests the company is meeting its goals. The acquisition of stock options also indicates confidence in the company's future performance.
Positives
- The vesting of performance share awards indicates that AbbVie achieved certain performance goals set by the Compensation Committee.
- The acquisition of stock options suggests confidence in the future performance of AbbVie's stock.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting of performance-based awards suggests positive past performance.
Industry Context
Executive compensation through stock awards and options is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants and performance-based equity awards are standard components of executive compensation packages in the pharmaceutical industry.
- Companies like Johnson & Johnson (JNJ) and Pfizer (PFE) also utilize similar compensation structures to incentivize their executives.
- The vesting of performance-based awards is contingent upon achieving specific financial or operational targets, such as earnings per share or relative total shareholder return, which aligns with industry best practices.
Stakeholder Impact
- The vesting of performance-based awards can positively impact shareholder sentiment as it indicates the company is achieving its performance targets.
- Executive compensation packages can influence employee morale and retention.
Next Steps
- The shares related to the performance share awards will be issued to Siatis on February 28, 2025.
- The options become exercisable in annual increments starting February 13, 2026.
Key Dates
| Date | Description |
|---|---|
| February 17, 2022 | Date of grant for performance share award and performance-vesting restricted stock unit award. |
| February 16, 2023 | Date of grant for performance-vesting restricted stock unit award. |
| February 15, 2024 | Date of grant for performance-vesting restricted stock unit award and employee stock options. |
| February 13, 2025 | Date of transaction and release of performance-vesting restrictions. |
| February 28, 2025 | Date shares will be issued to the reporting person. |
| February 13, 2026 | First date options become exercisable. |
| February 13, 2027 | Second date options become exercisable. |
| February 13, 2028 | Third date options become exercisable. |
| February 12, 2035 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.